This article, published in The New England Journal of Medicine, details a randomized clinical trial conducted in China to evaluate the safety and immunogenicity of a split-virus, inactivated vaccine candidate against the 2009 pandemic influenza A (H1N1) virus. Findings suggest typical protection in the majority of subjects 12 to 60 years of age after receiving a single dose of hemagglutinin antigen without alum adjuvant, with younger and older subjects experiencing lesser immune responses. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Zhu F, Wang H, Fang H, et al.

Published: 2009

Resource types: Peer-reviewed journal

Diseases: Influenza

Topics: Vaccine safety; Disease/vaccine specific information

Regions: Asia